deferoxamine has been researched along with Brain Neoplasms in 7 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| " 5-aminolevulinic acid (ALA) is metabolized to fluorescent protoporphyrin IX (PpIX) specifically in tumor cells, and therefore clinically used as a reagent for photodynamic diagnosis (PDD) and therapy (PDT) of cancers including gliomas." | 7.85 | Enhancement of 5-aminolevulinic acid-based fluorescence detection of side population-defined glioma stem cells by iron chelation. ( Hagiya, Y; Kokubu, Y; Murota, Y; Ogura, SI; Sugiyama, Y; Tabu, K; Taga, T; Wang, W, 2017) |
| "A phase II trial of a single 5-day course of deferoxamine in 9 patients with neuroblastomas was completed." | 7.68 | Effects of a single course of deferoxamine in neuroblastoma patients. ( Castello, MA; Deb, G; Dominici, C; Donfrancesco, A; Helson, L; Pileggi, D, 1990) |
| " 5-aminolevulinic acid (ALA) is metabolized to fluorescent protoporphyrin IX (PpIX) specifically in tumor cells, and therefore clinically used as a reagent for photodynamic diagnosis (PDD) and therapy (PDT) of cancers including gliomas." | 3.85 | Enhancement of 5-aminolevulinic acid-based fluorescence detection of side population-defined glioma stem cells by iron chelation. ( Hagiya, Y; Kokubu, Y; Murota, Y; Ogura, SI; Sugiyama, Y; Tabu, K; Taga, T; Wang, W, 2017) |
| "A phase II trial of a single 5-day course of deferoxamine in 9 patients with neuroblastomas was completed." | 3.68 | Effects of a single course of deferoxamine in neuroblastoma patients. ( Castello, MA; Deb, G; Dominici, C; Donfrancesco, A; Helson, L; Pileggi, D, 1990) |
| "Glioblastoma multiforme are highly invasive brain tumors." | 1.34 | Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells. ( Elstner, A; Holtkamp, N; von Deimling, A, 2007) |
| "Deferoxamine is an effective iron chelator and a potential therapeutic agent for use in minimizing free radical-mediated injury following trauma." | 1.30 | Screening of transcriptionally regulated genes following iron chelation in human astrocytoma cells. ( Connor, JR; Ye, Z, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lo Dico, A | 1 |
| Valtorta, S | 1 |
| Martelli, C | 1 |
| Belloli, S | 1 |
| Gianelli, U | 1 |
| Tosi, D | 1 |
| Bosari, S | 1 |
| Degrassi, A | 1 |
| Russo, M | 1 |
| Raccagni, I | 1 |
| Lucignani, G | 1 |
| Moresco, RM | 1 |
| Ottobrini, L | 1 |
| Wang, W | 1 |
| Tabu, K | 1 |
| Hagiya, Y | 1 |
| Sugiyama, Y | 1 |
| Kokubu, Y | 1 |
| Murota, Y | 1 |
| Ogura, SI | 1 |
| Taga, T | 1 |
| Dayani, PN | 1 |
| Bishop, MC | 1 |
| Black, K | 1 |
| Zeltzer, PM | 1 |
| Elstner, A | 1 |
| Holtkamp, N | 1 |
| von Deimling, A | 1 |
| Philipov, P | 1 |
| Ye, Z | 1 |
| Connor, JR | 1 |
| Donfrancesco, A | 1 |
| Deb, G | 1 |
| Dominici, C | 1 |
| Pileggi, D | 1 |
| Castello, MA | 1 |
| Helson, L | 1 |
1 review available for deferoxamine and Brain Neoplasms
| Article | Year |
|---|---|
Desferoxamine (DFO)--mediated iron chelation: rationale for a novel approach to therapy for brain cancer.
Topics: Brain Neoplasms; Deferoxamine; Humans; Iron; Iron Chelating Agents | 2004 |
6 other studies available for deferoxamine and Brain Neoplasms
| Article | Year |
|---|---|
Validation of an engineered cell model for in vitro and in vivo HIF-1α evaluation by different imaging modalities.
Topics: Animals; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Shape; Deferoxamine; Glioma; Humans; | 2014 |
Enhancement of 5-aminolevulinic acid-based fluorescence detection of side population-defined glioma stem cells by iron chelation.
Topics: Aminolevulinic Acid; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biotransforma | 2017 |
Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells.
Topics: Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Separation; Deferoxamine; Flow Cytometry; | 2007 |
Suppression of tumor growth in experimental 9L gliosarcoma model by copper depletion.
Topics: Brain Neoplasms; Chelating Agents; Deferoxamine; Glioma; Humans; Penicillamine; Trace Elements | 1996 |
Screening of transcriptionally regulated genes following iron chelation in human astrocytoma cells.
Topics: Astrocytoma; Brain Neoplasms; Chelating Agents; Deferoxamine; Gene Expression Regulation, Neoplastic | 1999 |
Effects of a single course of deferoxamine in neuroblastoma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1990 |